ArticleJournal of cancer research and clinical oncology2023

Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.

Max S Topp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.